Want to see COO full AI Analyst Report?
COO Stock Chart & Stats
$72.68
$0.08(0.11%)
At close: 4:00 PM EDT
$72.68
$0.08(0.11%)
Day’s Range― - ―
52-Week Range$51.01 - $89.83
Previous Close$70.4
Volume1.47M
Average Volume (3M)5.08M
Market Cap
$11.06B
Enterprise Value$16.38B
Total Cash (Recent Filing)$154.70M
Total Debt (Recent Filing)$2.54B
Price to Earnings (P/E)20.2
Beta0.57
Next Earnings
Dec 03, 2026EPS Estimate
1.07Next Dividend Ex-DateN/A
Dividend Yield0.02%
Share Statistics
EPS (TTM)2.93
Shares Outstanding190,155,290
10 Day Avg. Volume3,635,835
30 Day Avg. Volume5,078,991
Financial Highlights & Ratios
PEG Ratio-8.14
Price to Book (P/B)1.70
Price to Sales (P/S)3.42
P/FCF Ratio32.24
Enterprise Value/Market Cap1.48
Enterprise Value/Revenue3.87
Enterprise Value/Gross Profit6.07
Enterprise Value/Ebitda17.99
Forecast
1Y Price Target
$64.83Price Target Upside-10.80% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)4.54
Revenue Forecast (FY)$4.24B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained top-line expansion indicates continued demand for Cooper’s women’s health and vision products. Revenue growth provides a foundation for operating leverage, supports investment in innovation and commercial execution, and can strengthen the company’s competitive position over the next several quarters.
Conservative Balance SheetManageable leverage gives Cooper financial flexibility to fund research, commercial expansion and strategic initiatives without excessive reliance on new borrowing. The improving debt-to-equity trend also reduces balance-sheet strain and provides greater resilience if operating conditions remain uneven.
Fertility Market PositionBroad-based fertility growth and reported market-share gains suggest CooperSurgical has a differentiated portfolio and strengthening customer relationships. Continued innovation, clinic adoption and favorable fertility-market fundamentals can support durable growth beyond individual product cycles or quarterly fluctuations.
Bears Say
Weak Cash ConversionThe sharp TTM decline in operating and free cash flow weakens earnings quality and reduces internally generated funds available for investment, debt reduction and shareholder returns. Cash conversion at roughly half of net income also increases dependence on working-capital normalization and improved execution.
Operating Margin CompressionThe substantial margin contraction shows that revenue growth is not currently translating proportionately into operating profit. Higher costs, foreign exchange and commercial investment may continue to pressure profitability, limiting operating leverage and making earnings more sensitive to execution setbacks.
Commercial Execution GapDifficulty converting contract wins into revenue indicates an execution weakness rather than a simple demand shortfall. Until sales coverage, marketing support and commercial processes catch up with the product portfolio, Cooper may under-monetize innovation and face slower growth despite customer interest.
Cooper Co News
COO FAQ
What was Cooper Co’s price range in the past 12 months?
Cooper Co lowest stock price was $51.01 and its highest was $89.83 in the past 12 months.
What is Cooper Co’s market cap?
Cooper Co’s market cap is $11.06B.
When is Cooper Co’s upcoming earnings report date?
Cooper Co’s upcoming earnings report date is Dec 03, 2026 which is in 42 days.
How were Cooper Co’s earnings last quarter?
Cooper Co released its earnings results on Sep 09, 2026. The company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.124 by $0.026.
Is Cooper Co overvalued?
According to Wall Street analysts Cooper Co’s price is currently Overvalued.
Does Cooper Co pay dividends?
Cooper Co pays a Semiannually dividend of $0.007 which represents an annual dividend yield of 0.02%. See more information on Cooper Co dividends here
What is Cooper Co’s EPS estimate?
Cooper Co’s EPS estimate is 1.07.
How many shares outstanding does Cooper Co have?
Cooper Co has 190,155,290 shares outstanding.
What happened to Cooper Co’s price movement after its last earnings report?
Cooper Co reported an EPS of $1.15 in its last earnings report, beating expectations of $1.124. Following the earnings report the stock price went down -14.666%.
Which hedge fund is a major shareholder of Cooper Co?
Currently, no hedge funds are holding shares in COO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cooper Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$64.83 (-10.80% Downside)
$64.83 (-10.80% Downside)
Blogger Sentiment
Neutral
COO Sentiment 50%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 2.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $541.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.16%
12-Months-Change
Fundamentals
Return on Equity
6.88%
Trailing 12-Months
Asset Growth
2.40%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cooper Co
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.
COO Company Deck
COO Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly positive: the company delivered an earnings beat, record quarterly free cash flow, an 86% year-to-date free cash flow increase, a favorable tax resolution, substantial share repurchases and continued fertility and product momentum. These strengths were tempered by flat CooperVision revenue, U.S. channel destocking that will continue into Q4, legacy hydrogel declines, China and Asia Pacific challenges, near-term margin pressure and a higher expected fiscal 2027 tax rate. Management expressed confidence that inventory actions will be completed in Q4 and that increased commercial investment will support improved growth.View all COO earnings summariesCOO Net sales Breakdown
67.05% CooperVision
32.95% CooperSurgical
COO Stock 12 Month Forecast
Average Price Target
$64.83
▼(-10.80% Downside)
Technical Analysis
Baxter International
―
Merit Medical Systems
―
Staar Surgical
―
Teleflex
―
Bausch + Lomb Corporation
―
Ownership Overview
0.62% Insiders
36.08% Mutual Funds
1.19% Other Institutional Investors
32.07% Public Companies and
Individual Investors